Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0CFSEA
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
IN202417078684A+ADC10
|
|||||
| Synonyms |
IN202417078684A+ADC10
Click to Show/Hide
|
|||||
| Organization |
TAIHO PHARMACEUTICAL CO., LTD.
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
4
|
|||||
| Structure |
|
|||||
| Antibody Name |
IN202417078684A+Ab4
|
Antibody Info | Antigen Name |
Undisclosed
|
||
| Payload Name |
Active metabolite of irinotecan SN38
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
| Combination Type |
MC-CL2-SN-38
|
|||||
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC51) |
2330 ng/ml
|
|||
| Method Description |
The cytotoxicity of ADC against cell lines was evaluated by cell viability test with CellTiter-Glo 2.1 luminescence method.
|
||||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
244 ng/ml
|
|||
| Method Description |
The cytotoxicity of ADC against cell lines was evaluated by cell viability test with CellTiter-Glo 2.0 luminescence method.
|
||||